Related Experiment Video
Updated: Jun 12, 2025
Assessment of the Metabolic Profile of Primary Leukemia Cells
Published on: November 21, 2018
Assessing potential risk factors for metamizole-induced leukopenia
Birgit Brüne1, Sarah Sonderer1,2, Maria Bösing1,2
1University Center of Internal Medicine, Cantonal Hospital Baselland, Liestal, Switzerland.
Background:
Metamizole is a non-opioid analgesic agent that can rarely cause agranulocytosis, a severe form of leukopenia.
Objectives:
The aim of this study was to assess previously identified potential risk factors for the development of metamizole-induced leukopenia.
Design:
A retrospective, observational, matched case-control study was performed in a single-center setting.
Methods:
Patients who developed leukopenia in the setting of metamizole therapy were included as cases and matched 1:3 on the basis of age and sex to control patients who did not develop leukopenia when treated with metamizole. The data were obtained from the medical records of patients hospitalized at Cantonal Hospital Baselland between 2015 and 2020. Univariate and multivariate analyses were performed.
Results:
Eighty-six cases and 258 matched controls aged between 18 and 102 years were included. Fifty-seven percent were female. Previous leukopenic episodes (odds ratio (OR): 4.02, 95% CI: 1.95-8.28, p < 0.001) and a history of penicillin allergy (OR: 2.49, 95% CI: 1.03-6.03, p = 0.044) were found to be independent risk factors for metamizole-induced leukopenia.
Conclusion:
A history of previous leukopenic episodes and a history of penicillin allergy were confirmed as risk factors for metamizole-induced leukopenia. In our opinion, metamizole should be avoided in patients with these risk factors.
Insights
Metamizole can cause leukopenia, a serious blood disorder. Previous leukopenic episodes and penicillin allergy are confirmed risk factors, suggesting metamizole should be avoided in such patients.
Area of Science:
- Pharmacovigilance
- Hematology
- Clinical Pharmacology
Background:
- Metamizole is a non-opioid analgesic with a rare risk of agranulocytosis, a severe form of leukopenia.
- Identifying risk factors for metamizole-induced leukopenia is crucial for patient safety.
Purpose of the Study:
- To assess previously identified potential risk factors for metamizole-induced leukopenia.
- To confirm independent risk factors associated with metamizole-induced leukopenia.
Main Methods:
- A retrospective, observational, matched case-control study.
- Inclusion of 86 cases with metamizole-induced leukopenia and 258 matched controls.
- Univariate and multivariate analyses of patient medical records from 2015-2020.
Main Results:
- Previous leukopenic episodes were a significant risk factor (OR: 4.02, p < 0.001).
- A history of penicillin allergy was also identified as an independent risk factor (OR: 2.49, p = 0.044).
Conclusions:
- Previous leukopenic episodes and penicillin allergy are confirmed risk factors for metamizole-induced leukopenia.
- Metamizole use should be carefully considered and potentially avoided in patients with these identified risk factors.
Related Concept Videos
01:27Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...